Last reviewed · How we verify

Intranasal Ketorolac Tromethamine — Competitive Intelligence Brief

Intranasal Ketorolac Tromethamine (Intranasal Ketorolac Tromethamine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal anti-inflammatory drug (NSAID). Area: Pain Management.

phase 3 Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase (COX-1 and COX-2) Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Intranasal Ketorolac Tromethamine (Intranasal Ketorolac Tromethamine) — Tehran University of Medical Sciences. Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and provide rapid pain relief and anti-inflammatory effects.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Intranasal Ketorolac Tromethamine TARGET Intranasal Ketorolac Tromethamine Tehran University of Medical Sciences phase 3 Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase (COX-1 and COX-2)
Ketorolac Nasal Spray Ketorolac Nasal Spray Hersh, Elliot V., DMD, MS, PhD marketed Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase (COX-1 and COX-2)
Pranoprofen Eyedrops Pranoprofen Eyedrops Università degli Studi di Brescia marketed Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase (COX-1, COX-2)
Bromfenac Sodium 0.07% Bromfenac Sodium 0.07% Retina Research Institute, LLC marketed Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase (COX-1 and COX-2)
Topical diclofenac sodium gel Topical diclofenac sodium gel Guang'anmen Hospital of China Academy of Chinese Medical Sciences marketed Nonsteroidal anti-inflammatory drug (NSAID) COX-1 and COX-2 enzymes
aspirin + celecoxib aspirin + celecoxib Seoul National University Hospital marketed Nonsteroidal anti-inflammatory drug (NSAID) combination COX-1 and COX-2 enzymes
Plain aspirin Plain aspirin Royal College of Surgeons, Ireland marketed Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID) class)

  1. Università degli Studi di Brescia · 4 drugs in this class
  2. Bausch & Lomb Incorporated · 4 drugs in this class
  3. Bayer · 3 drugs in this class
  4. Pfizer · 3 drugs in this class
  5. Azienda USL Reggio Emilia - IRCCS · 3 drugs in this class
  6. Organon and Co · 3 drugs in this class
  7. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 2 drugs in this class
  8. Bezmialem Vakif University · 2 drugs in this class
  9. Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 2 drugs in this class
  10. Center For Excellence In Eye Care · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Intranasal Ketorolac Tromethamine — Competitive Intelligence Brief. https://druglandscape.com/ci/intranasal-ketorolac-tromethamine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: